Some people have defects on the gene SLC22A5, giving them problems with their OCTN2 transport protein (Organic cation transport).
OCTN2 transports carnitine into the mitochondial matrix where it can be used to create cellular energy.
Treatment indications for individuals with the defect on SLC22A5 includes oral or intravenous carnitine supplementation.
But one piece is missing...
If their OCTN2 is defective, then how does supplementing carnitine solve the problem? If they are deficient or lacking in OCTN2, how does carnitine even enter the mitochondrial matrix? (with no functional OCTN2 to transport it through?)
But the condition of these patients often improves with supplementation. So the carnitine is getting in there somehow.
Is there another route via which carnitine enters into the mitochondrial matrix?